APAC IPOs & Placements

Zhen Zhou, Toh

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<a href="https://www.smartkarma.com/entities/23679" target="_blank" data-smartkarma-citation="entities:23679:1">WuXi Biologics (2269 HK)</a> is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares.  Proceeds will be used for CapEx, repayment of outstanding debt, and working capital.There has already been good coverage on Smartkarma by <a href="https://www.smartkarma.com/profiles/13" target="_blank" data-smartkarma-citation="accounts:13">Kemp Dolliver, CFA</a>. He analyzed the company in <a href="https://www.smartkarma.com/insights/an-early-look-at-wuxi-biologics" target="_blank" data-smartkarma-citation="insights:8498">An Early Look at WuXi Biologics</a> and discussed valuations <a href="https://www.smartkarma.com/insights/wuxi-biologics-updated-valuation-data" target="_blank">here </a>and <a href="https://www.smartkarma.com/insights/wuxi-biologics-pass-on-this-valuation" target="_blank">here</a>. In this insight, we will add to Kemp's analysis, analyze the company's competitive advantage and compare its valuation with other listed peers. As usual, we will also run the deal through our ECM framework.

WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares.  Proceeds will be used for CapEx, repayment of outstanding debt, and working capital.There has already been good coverage on Smartkarma by Kemp Dolliver, CFA. He analyzed the company in An Early Look at WuXi Biologics and discussed valuations here and here. In this insight, we will add to Kemp's analysis, analyze the company's competitive advantage and compare its valuation with other listed peers. As usual, we will also run the deal through our ECM framework.

WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China

United States

Patheon N.V. operates as a provider of outsourced pharmaceutical development and manufacturing services. The Company offers customizable range of active pharmaceutical ingredient and finished drug product services to customers, from formulation development to clinical and commercial-scale manufacturing, packaging, and life cycle management.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Patheon N.V. (PTHN US)

WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China

WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Proceeds will be used...

Zhen Zhou, Toh

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)